JP Morgan raised the price target for the CytomX Therapeutics Inc (NASDAQ:CTMX) stock from “an Underweight” to “a Neutral”. The rating was released on April 22, 2024, according to finviz. We previously noted in another research note published on November 14, 2022 by BMO Capital Markets that downgraded the stock from an Outperform to a Market perform with a price target of $2.60 for CTMX stock. The research report from Wedbush has downgraded the stock from Outperform to Neutral, with a price target set at $2. The stock was downgraded by Piper Sandler, who disclosed in a research note on July 07, 2022, from Overweight to Neutral and set the price objective to $1.50. In their research brief published July 07, 2022, Mizuho analysts downgraded the CytomX Therapeutics Inc stock from Buy to Neutral with a price target of $4.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 178.62% within the last five trades and 115.05% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 310.19% in the last 6 months and 199.32% was added to its value over the previous 3 months. CTMX stock is trading at a margin of 108.08%, 102.93% and 172.11% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of the close of trading, CTMX deals in the Healthcare domain. The stock is trading -24.27 percent below its 52-week high and 325.96 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -23.39. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does CytomX Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 1.47 percent and the profit margin is -0.56 percent, and the company has reported a gross margin of 95.12 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $301.86 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 2.98 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.84 percent of CytomX Therapeutics Inc shares are owned by insiders, and 47.82 percent are held by financial institutions. McCarthy Sean A., the CEO at CytomX Therapeutics Inc (CTMX) has sold 20,223 shares of firm on Mar 19 ’24 at a price of $2.09 against the total amount of $42175.0. In another inside trade, BELVIN MARCIA, SVP, Chief Scientific Officer of CytomX Therapeutics Inc (NASDAQ:CTMX) sold 12,795 shares of the firm on Mar 19 ’24 for a total worth of $26684.0 at a price of $2.09. An inside trade which took place on Mar 19 ’24, Chief Business Officer of CytomX Therapeutics Inc Landau Jeffrey B sold 6,562 shares of firm against total price of $13685.0 at the cost of $2.09 per share.
